Amplia Therapeutics Ltd. · ASX:ATX
Amplia Therapeutics — Shareholder Meeting (August 2026)
19 slides from Amplia Therapeutics's shareholder meeting presentation, Aug 28, 2026
Slide 1: ASX Release: CEO & Managing Director's Presentation to AGM
28 AUGUST 2026 ASX RELEASE CEO & MANAGING DIRECTOR’S PRESENTATION TO ANNUAL GENERAL MEETING Melbourne, Australia: Amplia Therapeutics Limited (ASX:ATX; OTCQB:INNMF), (“Amplia” or the “Company”), is pleased to release the CEO & Managing Director’s presentation to the Company’s Annual General Meeting
Slide 2: Progress in the development of narmafotinib
AGM Presentation For personal use only Progress in the development of narmafotinib Dr Chris Burns CEO and MD 28 August 2026 ampliatx.com | @ampliatx ASX: ATX | OTCQB: INNMF 1
Slide 3: Disclaimer
Disclaimer 2 This presentation (Presentation) contains summary information about Amplia Therapeutics Limited ACN Forward-looking statements are based on the Company’s good faith assumptions as to the financial 165 160 841 and its subsidiaries (the Company or Amplia) which is current as at 30 June 20
Slide 4: Introduction: Highlights and Strategy
For personal use only Introduction Highlights and Strategy 6
Slide 5: Development Highlights
Development Highlights 4 Outstanding results across a range of activities and therapeutic areas Preclinical data illustrating narmafotinib’s efficacy in combination with chemotherapy and targeted drugs, in a range of cancer models including pancreatic, ovarian and lung cancer For personal use only C
Slide 6: Development Strategy
Development Strategy 5 Building a robust dataset demonstrating narmafotinib’s benefit What we have achieved Where we are currently What we are building towards For personal use only Clinical Trials Registrational trial Product Licence Demonstrating aligned with to third party/ies for benefit in defi
Slide 7: ACCENT Trial in pancreatic cancer
For personal use only ACCENT Trial in pancreatic cancer Excellent tolerability and responses observed 6
Slide 8: ACCENT Pancreatic Cancer Trial
ACCENT Pancreatic Cancer Trial 7 Narmafotinib + gemcitabine and Abraxane in first-line advanced pancreatic cancer For personal use only 7.8% 70% 11.1months months No Extra Burden Complete Disease Median Safety & response rate control rate overall survival tolerability Chemo alone (~0.2%) Chemo alone
Slide 9: ACCENT registration pathway
ACCENT registration pathway 8 A three-part registration pathway designed around FDA feedback Underway ACCENT Mini ACCENT Reg - P2b ACCENT Reg - P3 For personal use only Daily dosing at two dose levels Builds on ACCENT Mini data to Pivotal registrational study GnP combination compare the two daily do
Slide 10: PRROSE Trial in Ovarian Cancer
For personal use only PRROSE Trial in Ovarian Cancer Building on promising preclinical studies and literature data
Slide 11: PRROSE Trial
PRROSE Trial 10 Combining narmafotinib with standard-of-care chemotherapy An investigator-initiated pilot study led by Dr Gwo Yaw Ho of Monash Health and Monash University, and sponsored and coordinated through ANZGOG For personal use only TRIAL PARTNER ANZGOG Australia New Zealand Gynaecological On
Slide 12: kRAS Inhibitors
For personal use only kRAS Inhibitors An exciting new class of anti-cancer therapies - well suited for FAK inhibitor combination 14
Slide 13: kRAS mutations prevalent in cancer
kRAS mutations prevalent in cancer 12 Significant cancer driver in multiple cancers; multiple drugs in development For personal use only Chart: See Trends in Canc. 2025, 11, 91-116.
Slide 14: kRAS mutations prevalent in cancer
kRAS mutations prevalent in cancer 13 Significant cancer driver in multiple cancers; multiple drugs in development Clinical studies demonstrating For personal use only good activity but resistance and tolerability a significant issue1 60+ kRAS drugs now in clinical development2 Across pancreatic can
Slide 15: Narmafotinib and kRAS inhibition
Narmafotinib and kRAS inhibition 14 Overcoming acquired resistance to kRAS inhibitors FAK signaling is an escape mechanism to For personal use only blockade of RAS pathway1 Growing evidence for benefit of FAK + kRAS inhibition • Multiple preclinical studies, including Amplia’s own work, showing impr
Slide 16: Lilly Collaboration
For personal use only Lilly Collaboration kRAS G12C - FAK inhibitor combination 14
Slide 17: Lilly Collaboration: olomorasib combination study
Lilly Collaboration 16 Enhancing efficacy for next-generation kRAS G12C inhibitor olomorasib Previously treated KRAS G12C-mutant advanced or metastatic NSCLC For personal use only Olomorasib - a next-generation Phase 1b/2b study kRAS G12C inhibitor1 • Australian and US sites • Improved potency and s
Slide 18: Estimated Development Timeline
Estimated Development Timeline 17 2026 2027 2028 2029 ACCENT For personal use only ACCENT-mini safety data ACCENT-reg FDA Meeting FDA Meeting KRASi arm Olomorasib combination Potential second KRASi combination PRROSE
Slide 19: Chris Burns, CEO and MD
For personal use only Chris Burns PhD GAICD FAHMS CEO and MD chris@ampliatx.com Amplia Therapeutics Limited ASX: ATX | OTCQB: INNMF info@ampliatx.com ampliatx.com
Amplia Therapeutics — Shareholder Meeting (August 2026) on 6ix